Dialdehyde starch nanoparticles : an emerging material for anticancer drug delivery
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 18(2023), 11 vom: 13. Mai, Seite 849-854 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prasher, Parteek [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.08.2023 Date Revised 10.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2023-0018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35950194X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35950194X | ||
| 003 | DE-627 | ||
| 005 | 20231226081019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2023-0018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM35950194X | ||
| 035 | |a (NLM)37449452 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prasher, Parteek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dialdehyde starch nanoparticles |b an emerging material for anticancer drug delivery |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2023 | ||
| 500 | |a Date Revised 10.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a curcumin | |
| 650 | 4 | |a dialdehyde starch | |
| 650 | 4 | |a doxorubicin | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a esterification | |
| 650 | 4 | |a imine linkage | |
| 650 | 4 | |a magnetofection | |
| 650 | 4 | |a pH responsiveness | |
| 650 | 4 | |a paclitaxel | |
| 650 | 4 | |a tumor microenvironment | |
| 650 | 7 | |a dialdehyde starch |2 NLM | |
| 650 | 7 | |a 9047-50-1 |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Curcumin |2 NLM | |
| 650 | 7 | |a IT942ZTH98 |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 700 | 1 | |a Sharma, Mousmee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 18(2023), 11 vom: 13. Mai, Seite 849-854 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:11 |g day:13 |g month:05 |g pages:849-854 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2023-0018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 11 |b 13 |c 05 |h 849-854 | ||